Otomycosis - Pipeline Insight, 2024

This “Otomycosis- Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Otomycosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Otomycosis Understanding

Otomycosis: Overview

Otomycosis is a fungal infection that affects one, or occasionally both, of the ears. There are nearly 60 different species of fungi that may be responsible for this infection. Common fungi include Aspergillus and Candida Sometimes bacteria can combine with the fungi and make the infection more complicated. Otomycosis is more common in tropical and warm regions because fungi can grow better in these areas. This infection is also more common during the summer months. People who swim in contaminated water are more likely to get Otomycosis. Even swimming or surfing in clean water can increase the risk. In addition, people who have weakened immune systems, trauma or injuries in the ear, eczema, or other chronic skin problems are at a higher risk of getting this type of infection.

Symptoms
The symptoms of Otomycosis include:

• Hearing loss, which can be mistaken for deafness
• Felling of fullness in the ear
• Redness in the ear
• Itching
• Pain
• Inflammation or swelling
• Flaky skin
• Ringing in the ears
• Discharge from the ears which can be white, yellow, gray, black or green

Diagnosis
The diagnosis of otomycosis relies on the patient's clinical history, the physical examination, an otoscopic examination under microscopic control, imaging studies of the head, and laboratory identification of the fungus. Radiologic studies include computed tomography (CT), magnetic resonance imaging (MRI), and nuclear imaging. Laboratory diagnosis includes direct microscopy, culture, and histopathology. The samples from the auditory canal contain debris and secretions that can be used for mycologic culture. Skin biopsy specimens and surgical material from the tympanic membrane, the residual space, and middle ear cavity may be used for histopathology. In selected cases of invasive fungal mastoiditis or meningitis, the detection of fungal antigen by enzyme-linked immunosorbent assay in serum and cerebrospinal fluid is beneficial.

Treatment
Firstly, a doctor usually needs to clean the ear. They may use a rinse or a suction tool to do this. Cleaning will get rid of debris or a buildup of material and allow the medication to work better. Next, the ear is cleaned and dried, as much as possible, to inhibit further growth of fungus. A doctor may prescribe eardrops that contain an antifungal agent. Research has shown that 1 percent clotrimazole eardrops show high rates of cure and prevention of recurrence. Eardrops may also contain econazole, miconazole, or amphotericin B, among other chemicals. Antifungals may also be in the form of a topical cream that is applied to the outer ear. Oral medications, such as itraconazole or voriconazole, are usually reserved for more severe infections, or infections that are difficult to get rid of with topical agents. Some fungus species are resistant to antifungal eardrops. Oral antifungals can be a problem for people who have liver disease. Over-the-counter pain relievers, such as acetaminophen or ibuprofen, can be used to ease any minor pain.

Otomycosis Emerging Drugs Chapters

This segment of the Otomycosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Otomycosis Emerging Drugs

Miconazole: Hill Pharmaceuticals Miconazole is being developed by Hill pharmaceuticals for the treatment of Otomycosis. The drug is currently in Phase II/III of trial of clinical study. It acts as 14-alpha demethylase inhibitors, cell membrane modulators, cholesterol synthesis inhibitors. The trial got initiated in July 2020 and is expected to get completed by December 2021 with 390 expected enrolled participants.

Otomycosis: Therapeutic Assessment

This segment of the report provides insights about the different Otomycosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Otomycosis

There are approx. 10+ key companies which are developing the therapies for OtomycosisS. The companies which have their Otomycosis drug candidates in the most advanced stage, i.e. phase III include, Hill Pharmaceuticals.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Otomycosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Otomycosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Otomycosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Otomycosis drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Otomycosis R&D. The therapies under development are focused on novel approaches to treat/improve Otomycosis.

Otomycosis Report Insights

• Otomycosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Otomycosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Otomycosis drugs?
• How many Otomycosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Otomycosis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Otomycosis?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Otomycosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Hill Pharmaceuticals

Key Products

• Miconazole

This product will be delivered within 1-3 business days.